Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has
been filed against Clovis Oncology, Inc. (“Clovis” or the
“Company”) (NASDAQ: CLVS).
Investors who purchased or otherwise acquired shares between October 31,
2013 and November 15, 2015, inclusive (the “Class Period”) are
encouraged to contact the Firm prior to the January 19, 2016 lead
plaintiff motion deadline.
If you purchased shares of Clovis during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
According to the complaint, the Company issued materially false and
misleading statements to investors and/or failed to disclose that (1)
the New Drug Application (“NDA”) that Clovis submitted to the FDA for
rociletinib contained immature data sets based on both unconfirmed
response rates and confirmed response rates; (2) Clovis’ Breakthrough
Therapy designation submission contained immature data set based
primarily on unconfirmed responses; (3) Clovis presented interim data
publicly and at medical meetings that included a data set based
primarily on unconfirmed responses; and (4) as the efficacy data
matured, the number of patients with an unconfirmed response who
converted to a confirmed response was lower than expected. When the
truth was revealed, shares dropped causing investors harm.
If you purchased shares of Clovis during the Class Period, you have
until January 19, 2016 to ask the Court to appoint you as lead
plaintiff. If you wish to learn more about this lawsuit, or if you have
any questions concerning this notice or your rights, please contact Joon
M. Khang, a prominent litigator for almost two decades, by telephone:
(949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151213005041/en/
Copyright Business Wire 2015